Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009.
Abbott Reports Strong First Quarter Results
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2010. Worldwide sales increased 14.6 percent to $7.7 billion, including a favorable 4.1 percent effect of exchange rates.
Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
- Details
- Category: Novartis
Sandoz has signed a definitive agreement to acquire Oriel Therapeutics, a privately held US pharmaceuticals company, gaining exclusive rights to a portfolio of generic drug candidates and related technologies targeting medicines in the inhalable respiratory drug market.
Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
- Details
- Category: Bayer
To mark World Hemophilia Day, Bayer HealthCare is reaffirming its commitment to the global hemophilia community by pledging EUR 250,000 to the World Federation of Hemophilia (WFH).
Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
- Details
- Category: Novo Nordisk
Novo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia.
Long-term efficacy and tolerability of Vimpat® (lacosamide)
- Details
- Category: Clinical Trials
UCB's antiepileptic drug (AED) Vimpat® (lacosamide) featured in several studies and analyses presented at the 62nd annual American Academy of Neurology (AAN) meeting. These data offer additional clinical evidence supporting the use of lacosamide as adjunctive therapy in the treatment of adult patients with partial-onset seizures.
Stemgent and Pfizer Announce Collaboration
- Details
- Category: Pfizer
Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent.
More Pharma News ...
- Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market
- Additional Alemtuzumab Mechanism of Action Data Reported
- A potential first-in-class, once-daily oral therapy for relapsing forms of multiple sclerosis
- Sanofi-aventis and CureDM Sign Exclusive Worldwide License Agreement
- Nycomed and Baxter receive FDA approval for TachoSil®
- Novel agent Lu AE04621 enters Lundbeck's development pipeline
- Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciences